Evidence map›Paper›PMID 39921588›Full record

ArticleJournal of psychopharmacology (Oxford, England)2025

A single injection of neuropeptide QRFP in the lateral hypothalamus decreased food intake.

Olga Zagorácz, Tamás Ollmann, László Péczely, Kristóf László, Anita Kovács, Beáta Berta, Veronika Kállai, Erika Kertes, Dávid Vörös, Daniella Dusa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Olga ZagoráczInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.ORCID 0009-0002-5038-0753
Tamás OllmannInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
László PéczelyInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.ORCID 0000-0002-1754-5651
Kristóf LászlóInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Anita KovácsInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Beáta BertaInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Veronika KállaiInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Erika KertesInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Dávid VörösInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Daniella DusaInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
Ádám SzábóInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.
László LénárdInstitute of Physiology, University of Pécs Medical School, Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimSevere eating disorders, such as obesity, bulimia, and anorexia, keep increasing to epidemic proportions worldwide. Understanding of neuropeptides' role in complex hunger/satiety mechanisms may allow new prospects for treatment and prevention. Pyroglutamylated arginine-phenylalanine-amide peptides (QRFPs) are thought to enhance feeding following the central administration.

methodsIn our study, QRFP-26 was delivered into the lateral hypothalamic area of male Wistar rats by direct microinjections, as QRFP-26 expressing neurons and binding sights are densely present in this neural structure. The consumption of liquid food was measured over 60-min.

resultsBoth doses (100 and 200 ng) significantly decreased food intake compared to the control treatment. Neuropeptide Y Y1R/NPFF (neuropeptide FF) antagonist BIBP3226 eliminated the anorexigenic effect caused by QRFP-26 administration. QRFP-26 affects neither general locomotion, behavioral patterns examined in the Open Field Test, nor anxiety.

conclusionThis study is the first to report the anorexigenic action of QRFP-26 following direct administration into the hypothalamus, emphasizing steady locomotion and anxiety levels. We have shown that the effect of QRFP can be linked to the neuropeptide Y (NPY) Y1 or NPFF receptors.

Indexed as

EatingHypothalamic Area, LateralNeuropeptidesAnimalsArginineDose-Response Relationship, DrugIntercellular Signaling Peptides and ProteinsMaleMicroinjectionsRatsRats, WistarReceptors, NeuropeptideReceptors, Neuropeptide YArginineBIBP 3226Intercellular Signaling Peptides and Proteinsneuropeptide FF receptorNeuropeptidesneuropeptide Y-Y1 receptorQRFP peptideReceptors, NeuropeptideReceptors, Neuropeptide YappetiteCentral regulation of feedinghypothalamusNPFFNPYQRFP

Identifiers

PMID39921588
PMCPMC11843799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.